Progress in Clinical Research and Experimental Study of Danggui Shaoyao Powder in the Treatment of Chronic Pelvic Inflammatory Disease
10.13359/j.cnki.gzxbtcm.2024.04.041
- VernacularTitle:当归芍药散治疗慢性盆腔炎的临床研究及实验研究进展
- Author:
Zi-Yi FENG
1
;
Jia-Jun LIU
;
Lan WANG
;
Wan-Ying CHEN
;
Jie-Ming HUANG
Author Information
1. 广州中医药大学,广东广州 510006
- Keywords:
Danggui Shaoyao Powder;
chronic pelvic inflammatory disease(CPID);
clinical research;
experimental study;
review
- From:
Journal of Guangzhou University of Traditional Chinese Medicine
2024;41(4):1091-1096
- CountryChina
- Language:Chinese
-
Abstract:
Chronic pelvic inflammatory disease(CPID)is a common chronic inflammatory disease in women,and has a long course and is easy to relapse.Danggui Shaoyao Powder is from Jin Gui Yao Lve(Synopsis of the Golden Chamber),which was a commonly-used formula for the treatment of women's abdominal pain in ancient medical records.It is now often used in the treatment of CPID and has achieved satisfactory therapeutic effect.The article summarizes and analyzes the achievements in the clinical research and experimental study of Danggui Shaoyao Powder in the treatment of CPID over the past 10 years,and invesigates the clinical efficacy of Danggui Shaoyao Powder in the treatment of CPID and its therapeutic mechanism.In the field of clinical studies,Danggui Shaoyao Powder for the treatment of CPID was used by modification,or alone,or in combination with antibiotics and Chinese medicine external treatment,and its combined use was effective on significantly improving the indicators of inflammatory response and immune function,alleviating the clinical signs and symptoms such as pain,and did not increase the incidence of adverse reactions compared with the application of western medicines alone.In the field of experimental studies,Danggui Shaoyao Powder played the therapeutic role in CPID by decreasing the adhesion of endothelial cells,regulating the degradation of extracellular matrix,improving the level of inflammatory factors,and down-regulating the expression of proteins related to the nuclear factor κB(NF-κB)pathway.
